Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3694
-0.0106 (-2.79%)
Aug 13, 2025, 4:00 PM EDT - Market closed
Vaxart Revenue
Vaxart had revenue of $39.73M in the quarter ending June 30, 2025, with 520.68% growth. This brings the company's revenue in the last twelve months to $80.72M, up 479.58% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
$80.72M
Revenue Growth
+479.58%
P/S Ratio
1.04
Revenue / Employee
$768,800
Employees
105
Market Cap
84.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VXRT News
- 12 hours ago - Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 hours ago - US orders Vaxart to stop COVID-19 trial amid mRNA wind down - Reuters
- 20 days ago - Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq - GlobeNewsWire
- 2 months ago - Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - GlobeNewsWire
- 2 months ago - Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewsWire
- 2 months ago - Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - GlobeNewsWire